Literature DB >> 5311056

Therapy of leprosy.

J Convit, S G Browne, J Languillon, J H Pettit, K Ramanujam, F Sagher, J Sheskin, G Tarabini, L de Souza Lima, J G Tolentino, M F Waters, L M Bechelli, V Martínez Domínguez.   

Abstract

The latest developments and ideas in the therapy of leprosy are discussed, the need for long-term studies being stressed. The therapeutic efficacy and effective dosages of some sulfones (especially diaphenylsulfone), thiambutosine and long-acting sulfonamides such as sulfamethoxine and sulfalene, are considered. The possibilities for two newer drugs, 4,4'-diacetyldiaminodiphenylsulfone and clofazimine (B-663), both still in the early stages of evaluation, are also described and the potential value of thalidomide in treatment of the lepra reaction is discussed. The authors make a number of recommendations for controlled trials and lines of investigation and, in particular, favour a biochemical approach to the correction of defective host defences. Diaphenylsulfone is still considered the drug of choice for use in the therapy of leprosy.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5311056      PMCID: PMC2427498     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

1.  Artificial cellular immunity against tubercle bacilli; an effect of polyoxyethylene ethers (Triton).

Authors:  G B MACKANESS
Journal:  Am Rev Tuberc       Date:  1954-05
  1 in total
  1 in total

1.  Some recent laboratory findings on Mycobacterium leprae. Implications for the therapy, epidemiology and control of leprosy.

Authors:  L M Bechelli; R S Guinto
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.